Biomedicine, regarded as one of Shanghai's core industries, has gradually resumed operations in the Zhangjiang Hi-tech Park, Pudong New Area, as the COVID-19 outbreak is under control.

A great number of innovative biomedicine companies focused on the research and development (R&D) of innovative medicines have made steady progress in resuming production.

Elpiscience, a clinical-stage biopharmaceutical business focused on cancer immunotherapy, has been approved to restart operations as part of the third batch of "white list" companies, and it has offered housing and stipends to its employees who are returning to work.

Elpiscience, based in Pudong's Zhangjiang Pharma Valley, is dedicated to preclinical pharmaceutical R&D, and its laboratory's R&D process will have a significant impact on the company's overall strategy.

"Our company has been actively communicating with the government since it announced the policy on work resumption, ensuring that the scientific research personnel can return to work as soon as possible," said Tu Shuyue, director of the company's president office.

A green channel has been established thanks to the efforts of the local government, allowing key staff members to return to work in a timely manner.

Another biomedicine enterprise in the valley, Mabwell, has acted quickly to respond to the government's appeal to resume operations and production while maintaining epidemic prevention and control measures.

More pharmaceutical items and medical supplies will be developed as more medical and pharmaceutical enterprises reopen for business and production, providing substantial guarantees for Shanghai's fight against COVID-19.

An Elpiscience researcher resumes work duties on-site in Pudong's Zhangjiang Pharmacy Valley. [Photo/WeChat account: pdnews]

Zhangjiang Pharma Valley, a hub that supports startups and early-stage projects at established companies, has nurtured over 380 biopharma companies and seen over 10 of them go public. [Photo/WeChat account: pdnews]